Cargando…
Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach
OBJECTIVE: To compare the efficacy of valsartan in systolic (SBP) and diastolic blood pressure (DBP) reduction with other angiotensin II receptor blockers (ARBs) in essential hypertension. METHODS: Systematic literature search of databases between October 1997 and May 2008. Meta-analysis of short-te...
Autores principales: | Nixon, R M, Müller, E, Lowy, A, Falvey, H |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2779985/ https://www.ncbi.nlm.nih.gov/pubmed/19392925 http://dx.doi.org/10.1111/j.1742-1241.2009.02028.x |
Ejemplares similares
-
Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and cancer risk: an updated meta-analysis of observational studies
por: Shin, Kayeong, et al.
Publicado: (2022) -
Effects of adding tripterygium glycosides to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on albuminuria in patients with diabetic nephropathy
por: Fang, Jin-Ying, et al.
Publicado: (2020) -
Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease
por: Huang, Rong-Shuang, et al.
Publicado: (2016) -
Clinical application of angiotensin receptor blockers in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis
por: Li, Yating, et al.
Publicado: (2018) -
Influence of angiotensin converting enzyme inhibitors/angiotensin receptor blockers on the risk of all‐cause mortality and other clinical outcomes in patients with confirmed COVID‐19: A systemic review and meta‐analysis
por: Jia, Na, et al.
Publicado: (2021)